Related Experiment Video
Updated: May 24, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Early-access Use of Radioligand Therapy in Prostate Cancer
Chloe François1, Clement Bailly1
1Nuclear Medicine Department, Nantes University Hospital, Nantes, France; Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, France.
European Urology Focus
|May 22, 2026
Summary
Radioligand therapy (RLT) using lutetium-177 PSMA-617 offers significant clinical benefits for metastatic castration-resistant prostate cancer. Early-access programs confirm its effectiveness and safety in real-world settings, guiding future treatment strategies.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) management has been advanced by PSMA-targeted radioligand therapy.
- Early-access programs provide crucial real-world data on novel therapies before widespread approval.
Purpose of the Study:
- To review the real-world evidence from early-access programs for PSMA-targeted radioligand therapy in mCRPC.
- To evaluate the clinical benefit, safety, and patient selection strategies for lutetium-177 PSMA-617.
Main Methods:
- Analysis of data from early-access programs for lutetium-177 PSMA-617.
- Assessment of clinical outcomes, safety profiles, and predictive factors in heterogeneous mCRPC populations.
Main Results:
- Lutetium-177 PSMA-617 demonstrated consistent clinical benefit and a tolerable safety profile in heavily pretreated patients.
- Low PSMA expression, liver metastases, and poor performance status were associated with worse outcomes.
- PSMA-PET imaging proved valuable for patient selection and response assessment.
Conclusions:
- Early-access programs validate the effectiveness and safety of PSMA-targeted RLT in routine clinical practice.
- These programs refine patient selection, response assessment, and inform treatment strategies like dosimetry-guided care.
- Findings support the integration of RLT into standard mCRPC management.
